Amir Shabaka

TL;DR: Treatment with corticosteroid-cyclophosphamide induced remission in a significantly greater number of patients with primary membranous nephropathy than tacrolimus-rituximab, and serious adverse events were similar in both groups.

TL;DR: Although patients who died presented with worse respiratory situation at admission, this was not significantly different at tocilizumab administration and did not have an impact on outcome in the multivariate analysis.

TL;DR: High-dose corticosteroid treatment for 3 weeks or prolonged treatment for >8 weeks were not associated with greater kidney function recovery in drug-induced acute interstitial nephritis, and a delay in the initiation of cortICosteroids resulted in worse recovery of kidney function.

TL;DR: The pathogenesis, clinical approach to distinguish between the different causes, and current recommendations in the management of focal segmental glomerulosclerosis are examined.

TL;DR: In this paper, a new generation of non-steroidal mineralocorticoid receptor antagonist has been developed to obtain a selective receptor inhibition reducing side effects like hyperkalemia and thereby making the drugs suitable for administration to CKD patients.